Karen Sofia Fernandez MD

Pediatric Hematology & Oncology•Madera, CA

Cancer Genetics/Cancer Risk Assessment, Hospice and Palliative Medicine(Pediatric Hematology and Oncology), Pediatric Solid Tumor Oncology

Director Solid Tumor Program. Clinical Professor of Pediatrics Stanford Medicine

Join to View Full Profile

9300 Children's Place DriveMadera, CA 93636
Phone+1 559-353-5480

Summary

Dr. Karen Fernandez is a pediatric hematologist/oncologist in Madera, CA. She received her medical degree from Universidiad Francisco Marroquin Faculty of Medicine and has been in practice 16 years. She also speaks multiple languages, including Spanish. She specializes in hospice and palliative medicine(pediatric hematology and oncology), pediatric sarcoma oncology, and pediatric solid tumor oncology and is experienced in global health, healthcare quality, medical education, and neoplasm drug resistance.

Education & Training

Mass General Brigham/Massachusetts General Hospital/Dana-Farber Cancer Institute/Brigham and Women's HospitalFellowship, Hospice and Palliative Medicine, 2012 - 2012
Nationwide Children's Hospital/Ohio State UniversityFellowship, Pediatric Hematology/Oncology, 2006 - 2009
University of Illinois College of Medicine at ChicagoResidency, Pediatrics, 2004 - 2006
University of Illinois College of Medicine at ChicagoInternship, Pediatrics, 2003 - 2004
Universidiad Francisco Marroquin Faculty of MedicineClass of 2001

Certifications & Licensure

CA State Medical License 2016 - 2026
IL State Medical License 2003 - 2017
OH State Medical License 2006 - 2011
American Board of Pediatrics Pediatrics
American Board of Pediatrics Hospice and Palliative Medicine
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
ACTIVE_NOT_RECRUITING
PHASE3
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
Completed
Phase 3
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Start of enrollment: 2005 Nov 14
Completed
Phase 3
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Start of enrollment: 2007 Feb 05
Completed
Phase 3
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma Start of enrollment: 2013 Aug 12
ACTIVE_NOT_RECRUITING
PHASE2
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Start of enrollment: 2014 Oct 08
Completed
Phase 2
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma Start of enrollment: 2014 Aug 01
Completed
Phase 2
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Join now to see all

Publications & Presentations

PubMed

Paraneoplastic juvenile idiopathic arthritis as a manifestation of a benign teratoma in a 5-year-old female.
Shivani Kamal, Sukesh Sukumaran, Christopher LePhong, Karen S Fernandez
Pediatric Blood & Cancer. 2023-10-01
2 citations
Alveolar soft part sarcoma: Prolonged response to immune checkpoint inhibitors.
Ruetima Titapiwatanakun, Crystal Farrell, Karen S Fernandez
Pediatric Blood & Cancer. 2023-05-12
1 citations
Brentuximab vedotin related neuropathy in a patient with Gilbert syndrome: Do mutations of UGT1A1 gene affect brentuximab toxicity?
Nicole Diebert, Katherine Baker, Karen S. Fernández
Pediatric Blood & Cancer. 2021-11-12

Lectures

Feasibility of brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in children and adolescents (< 18 years) with early relapse Hodg...
2019 ASCO Annual Meeting - 6/1/2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
American Academy of Hospice and Palliative Medicine - AAHPM
Member
American Academy of Pediatrics - AAP
Member
American Society of Pediatric Hematology Oncology
Member
Children's Oncology Group
Member
International Society of Pediatric Oncology (SIOP)
Member
Central American Asociation of Pediatric Oncology (AHOPCA)
Member

Other Languages

Spanish

External Links

Valley Children's Hospitalhttp://Valleychildrens.org
Childrens Hospital of Illinois http://www.childrenshospitalofillinois.org/services-and-clinics/specialty-services/hematology-oncology.html